HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. [electronic resource]
Producer: 20111221Description: 1134-42 p. digitalISSN:- 1474-5488
- Anthracyclines -- administration & dosage
- Antigens, Neoplasm -- genetics
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Chi-Square Distribution
- Clinical Trials, Phase III as Topic
- DNA Topoisomerases, Type II -- genetics
- DNA-Binding Proteins -- genetics
- Disease-Free Survival
- Evidence-Based Medicine
- Female
- Gene Amplification
- Gene Deletion
- Humans
- In Situ Hybridization, Fluorescence
- Kaplan-Meier Estimate
- Middle Aged
- Patient Selection
- Poly-ADP-Ribose Binding Proteins
- Precision Medicine
- Predictive Value of Tests
- Proportional Hazards Models
- Randomized Controlled Trials as Topic
- Receptor, ErbB-2 -- genetics
- Risk Assessment
- Risk Factors
- Survival Rate
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.